O
BHC icon

OrbiMed’s Bausch Health BHC Stock Holding History

OrbiMed’s Portfolio BHC Stock Details BHC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,399,880
Closed -$37.2M – 140
2020
Q1 		$37.2M Sell
2,399,880
-783,220
-25% -$18.9M 0.63% 46
2019
Q4 		$95.2M Sell
3,183,100
-129,200
-4% -$3.36M 1.36% 27
2019
Q3 		$72.4M Sell
3,312,300
-428,400
-11% -$9.8M 1.37% 24
2019
Q2 		$94.3M Hold
3,740,700
– – 1.46% 18
2019
Q1 		$92.4M Buy
3,740,700
+140,400
+4% +$3.35M 1.43% 19
2018
Q4 		$66.5M Buy
3,600,300
+1,696,400
+89% +$40.4M 1.23% 26
2018
Q3 		$48.9M Buy
+1,903,900
New +$43.6M 0.59% 52
2018
Q1 		– Sell
-76,800
Closed -$1.6M – 142
2017
Q4 		$1.6M Sell
76,800
-118,100
-61% -$1.87M 0.02% 125
2017
Q3 		$2.79M Hold
194,900
– – 0.03% 128
2017
Q2 		$3.37M Hold
194,900
– – 0.04% 124
2017
Q1 		$2.15M Hold
194,900
– – 0.02% 126
2016
Q4 		$2.83M Hold
194,900
– – 0.04% 118
2016
Q3 		$4.79M Hold
194,900
– – 0.05% 119
2016
Q2 		$3.92M Hold
194,900
– – 0.04% 114
2016
Q1 		$5.13M Sell
194,900
-195,100
-50% -$14.4M 0.05% 116
2015
Q4 		$39.6M Buy
390,000
+225,000
+136% +$25.3M 0.36% 58
2015
Q3 		$29.4M Hold
165,000
– – 0.3% 61
2015
Q2 		$36.7M Buy
165,000
+3,000
+2% +$665K 0.31% 63
2015
Q1 		$32.2M Hold
162,000
– – 0.27% 66
2014
Q4 		$23.2M Buy
162,000
+24,000
+17% +$3.23M 0.22% 70
2014
Q3 		$18.1M Hold
138,000
– – 0.19% 79
2014
Q2 		$17.4M Buy
138,000
+5,000
+4% +$638K 0.2% 68
2014
Q1 		$17.5M Sell
133,000
-24,000
-15% -$3.28M 0.22% 69
2013
Q4 		$18.4M Buy
157,000
+19,000
+14% +$2.08M 0.27% 67
2013
Q3 		$14.4M Hold
138,000
– – 0.26% 64
2013
Q2 		$11.9M Buy
+138,000
New +$10.9M 0.25% 70

Other funds holding BHC

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VH
ValueAct Holdings San Francisco, California $5.63B AUM 5.11% 1-Year Est. Return
GCM
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

OrbiMed's BHC Position: Q2 2020 in Review

OrbiMed sold out of Bausch Health (BHC) in Q2 2020, closing a stake of 2,399,880 shares — an estimated $37.2M sold.

OrbiMed first reported a position in BHC in Q2 2013 and held it in 26 quarters. The position peaked at $95.2M in Q4 2019. 303 funds tracked by Wall St. Rank hold BHC as of Q2 2020.

  • OrbiMed reported no remaining Bausch Health position as of Q2 2020 after selling out during the quarter.
  • OrbiMed sold 2,399,880 Bausch Health shares in Q2 2020, an estimated $37.2M.
  • OrbiMed first reported a position in Bausch Health in Q2 2013 and held it in 26 quarters.
  • OrbiMed's Bausch Health position peaked at $95.2M in Q4 2019.
  • 303 funds tracked by Wall St. Rank held Bausch Health as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.